These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 29566026)

  • 1. The p38 mitogen activated protein kinase inhibitor losmapimod in chronic obstructive pulmonary disease patients with systemic inflammation, stratified by fibrinogen: A randomised double-blind placebo-controlled trial.
    Fisk M; Cheriyan J; Mohan D; Forman J; Mäki-Petäjä KM; McEniery CM; Fuld J; Rudd JHF; Hopkinson NS; Lomas DA; Cockcroft JR; Tal-Singer R; Polkey MI; Wilkinson IB
    PLoS One; 2018; 13(3):e0194197. PubMed ID: 29566026
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of the p38 MAPK inhibitor losmapimod for patients with chronic obstructive pulmonary disease: a randomised, double-blind, placebo-controlled trial.
    Watz H; Barnacle H; Hartley BF; Chan R
    Lancet Respir Med; 2014 Jan; 2(1):63-72. PubMed ID: 24461903
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An oral inhibitor of p38 MAP kinase reduces plasma fibrinogen in patients with chronic obstructive pulmonary disease.
    Lomas DA; Lipson DA; Miller BE; Willits L; Keene O; Barnacle H; Barnes NC; Tal-Singer R;
    J Clin Pharmacol; 2012 Mar; 52(3):416-24. PubMed ID: 22090363
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biological effects of p38 MAPK inhibitor losmapimod does not translate to clinical benefits in COPD.
    Pascoe S; Costa M; Marks-Konczalik J; McKie E; Yang S; Scherbovsky PS
    Respir Med; 2017 Sep; 130():20-26. PubMed ID: 29206629
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A post-hoc subgroup analysis of data from a six month clinical trial comparing the efficacy and safety of losmapimod in moderate-severe COPD patients with ≤2% and >2% blood eosinophils.
    Marks-Konczalik J; Costa M; Robertson J; McKie E; Yang S; Pascoe S
    Respir Med; 2015 Jul; 109(7):860-9. PubMed ID: 26033641
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of p38 mitogen-activated protein kinase inhibition on vascular and systemic inflammation in patients with atherosclerosis.
    Elkhawad M; Rudd JH; Sarov-Blat L; Cai G; Wells R; Davies LC; Collier DJ; Marber MS; Choudhury RP; Fayad ZA; Tawakol A; Gleeson FV; Lepore JJ; Davis B; Willette RN; Wilkinson IB; Sprecher DL; Cheriyan J
    JACC Cardiovasc Imaging; 2012 Sep; 5(9):911-22. PubMed ID: 22974804
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Losmapimod, a novel p38 mitogen-activated protein kinase inhibitor, in non-ST-segment elevation myocardial infarction: a randomised phase 2 trial.
    Newby LK; Marber MS; Melloni C; Sarov-Blat L; Aberle LH; Aylward PE; Cai G; de Winter RJ; Hamm CW; Heitner JF; Kim R; Lerman A; Patel MR; Tanguay JF; Lepore JJ; Al-Khalidi HR; Sprecher DL; Granger CB;
    Lancet; 2014 Sep; 384(9949):1187-95. PubMed ID: 24930728
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Population pharmacokinetics of losmapimod in healthy subjects and patients with rheumatoid arthritis and chronic obstructive pulmonary diseases.
    Yang S; Lukey P; Beerahee M; Hoke F
    Clin Pharmacokinet; 2013 Mar; 52(3):187-98. PubMed ID: 23254770
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of Losmapimod on Cardiovascular Outcomes in Patients Hospitalized With Acute Myocardial Infarction: A Randomized Clinical Trial.
    O'Donoghue ML; Glaser R; Cavender MA; Aylward PE; Bonaca MP; Budaj A; Davies RY; Dellborg M; Fox KA; Gutierrez JA; Hamm C; Kiss RG; Kovar F; Kuder JF; Im KA; Lepore JJ; Lopez-Sendon JL; Ophuis TO; Parkhomenko A; Shannon JB; Spinar J; Tanguay JF; Ruda M; Steg PG; Theroux P; Wiviott SD; Laws I; Sabatine MS; Morrow DA;
    JAMA; 2016 Apr; 315(15):1591-9. PubMed ID: 27043082
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of antidepressant properties of the p38 MAP kinase inhibitor losmapimod (GW856553) in Major Depressive Disorder: Results from two randomised, placebo-controlled, double-blind, multicentre studies using a Bayesian approach.
    Inamdar A; Merlo-Pich E; Gee M; Makumi C; Mistry P; Robertson J; Steinberg E; Zamuner S; Learned S; Alexander R; Ratti E
    J Psychopharmacol; 2014 Jun; 28(6):570-81. PubMed ID: 24699061
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety, tolerability, pharmacokinetics, and pharmacodynamics of losmapimod in healthy Japanese volunteers.
    Ino H; Takahashi N; Terao T; Igarashi H; Sarai N
    Clin Pharmacol Drug Dev; 2015 Jul; 4(4):262-9. PubMed ID: 27136906
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analgesic efficacy and safety of the novel p38 MAP kinase inhibitor, losmapimod, in patients with neuropathic pain following peripheral nerve injury: a double-blind, placebo-controlled study.
    Ostenfeld T; Krishen A; Lai RY; Bullman J; Baines AJ; Green J; Anand P; Kelly M
    Eur J Pain; 2013 Jul; 17(6):844-57. PubMed ID: 23239139
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of BMS-582949, a P38 mitogen-activated protein kinase (P38 MAPK) inhibitor on arterial inflammation: a multicenter FDG-PET trial.
    Emami H; Vucic E; Subramanian S; Abdelbaky A; Fayad ZA; Du S; Roth E; Ballantyne CM; Mohler ER; Farkouh ME; Kim J; Farmer M; Li L; Ehlgen A; Langenickel TH; Velasquez L; Hayes W; Tawakol A
    Atherosclerosis; 2015 Jun; 240(2):490-6. PubMed ID: 25913664
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The study of LoSmapimod treatment on inflammation and InfarCtSizE (SOLSTICE): design and rationale.
    Melloni C; Sprecher DL; Sarov-Blat L; Patel MR; Heitner JF; Hamm CW; Aylward P; Tanguay JF; DeWinter RJ; Marber MS; Lerman A; Hasselblad V; Granger CB; Newby LK
    Am Heart J; 2012 Nov; 164(5):646-653.e3. PubMed ID: 23137494
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of the oral p38 inhibitor PH-797804 in chronic obstructive pulmonary disease: a randomised clinical trial.
    MacNee W; Allan RJ; Jones I; De Salvo MC; Tan LF
    Thorax; 2013 Aug; 68(8):738-45. PubMed ID: 23539534
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rationale and design of the LosmApimod To Inhibit p38 MAP kinase as a TherapeUtic target and moDify outcomes after an acute coronary syndromE trial.
    O'Donoghue ML; Glaser R; Aylward PE; Cavender MA; Crisp A; Fox KA; Laws I; Lopez-Sendon JL; Steg PG; Theroux P; Sabatine MS; Morrow DA
    Am Heart J; 2015 May; 169(5):622-630.e6. PubMed ID: 25965709
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-inflammatory effects of roflumilast in chronic obstructive pulmonary disease (ROBERT): a 16-week, randomised, placebo-controlled trial.
    Rabe KF; Watz H; Baraldo S; Pedersen F; Biondini D; Bagul N; Hanauer G; Göhring UM; Purkayastha D; Román J; Alagappan VKT; Saetta M
    Lancet Respir Med; 2018 Nov; 6(11):827-836. PubMed ID: 30224319
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A randomized, placebo-controlled trial of the analgesic efficacy and safety of the p38 MAP kinase inhibitor, losmapimod, in patients with neuropathic pain from lumbosacral radiculopathy.
    Ostenfeld T; Krishen A; Lai RY; Bullman J; Green J; Anand P; Scholz J; Kelly M
    Clin J Pain; 2015 Apr; 31(4):283-93. PubMed ID: 25751578
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety, tolerability, pharmacokinetics and pharmacodynamics of losmapimod following a single intravenous or oral dose in healthy volunteers.
    Barbour AM; Sarov-Blat L; Cai G; Fossler MJ; Sprecher DL; Graggaber J; McGeoch AT; Maison J; Cheriyan J
    Br J Clin Pharmacol; 2013 Jul; 76(1):99-106. PubMed ID: 23215699
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of p38 mitogen-activated protein kinase improves nitric oxide-mediated vasodilatation and reduces inflammation in hypercholesterolemia.
    Cheriyan J; Webb AJ; Sarov-Blat L; Elkhawad M; Wallace SM; Mäki-Petäjä KM; Collier DJ; Morgan J; Fang Z; Willette RN; Lepore JJ; Cockcroft JR; Sprecher DL; Wilkinson IB
    Circulation; 2011 Feb; 123(5):515-23. PubMed ID: 21262998
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.